Product Information |
|
Registration Number |
BR-523
|
Generic Name |
Diphtheria, Tetanus, Pertussis (Acellular Poliomyelitis (Inactivated) Vaccine and Haemophilus influenzae Type B Conjugate Vaccine (Adsorbed)
|
Brand Name |
Pentaxim
|
Dosage Strength |
After reconstitution, each dose (0.5 mL) contains:
Diphtheria toxoid
Tetanus toxoid
Bordetella pertussis antigen
Pertussis toxoid
Filamentous hemagglutinin Poliovirus (Inactivated)
>30 IU
>40 IU
Polysaccharide influenzae Type B Conjugated to tetanus protein
of
Haemophilus 10 mcg
18-30 mcg
25 mcg
25 mcg
Type I poliomyelitis virus (inactivated)
40 D antigen
units
Type II poliomyelitis virus (inactivated)
8 D antigen units
Type III poliomyelitis virus (inactivated)
32
D' antigen
|
Dosage Form |
Suspension and Powder for Suspension for Injection (IM)
|
Classification |
Prescription Drug (RX)
|
Packaging |
Type I pre-filled glass syringe with 2 separate needles + Type I glass vial (Box of 1's and Box of 10's)
|
Pharmacologic Category |
-
|
Manufacturer |
Sanofi Pasteur, Inc.
|
Country of Origin |
France
|
Trader |
N/A
|
Importer |
Sanofi Pasteur, Inc
|
Distributor |
Zuellig Pharma Corporation
|
Application Type |
Renewal
|
Issuance Date |
14 September 2023
|
Expiry Date |
21 August 2028
|